Osteoanabolic Agents for Osteoporosis

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Osteoporosis treatment involves antiresorptive and anabolic agents.
• Antiresorptive drugs inhibit bone resorption, while anabolic agents stimulate bone formation.
• Anabolic therapies are indicated for severe osteoporosis, treatment failures, or intolerance to other agents.

Purpose of the Study:

• To review the role and administration sequence of anabolic osteoporosis therapies.
• To discuss current approved anabolic agents and emerging treatments.
• To highlight the impact of drug sequencing on treatment efficacy.

Main Methods:

• Review of current literature on osteoporosis pharmacotherapy.
• Analysis of clinical trial data for anabolic agents (teriparatide, abaloparatide).
• Evaluation of drug interaction and sequencing effects on bone mineral density and fracture rates.

Main Results:

• Teriparatide and abaloparatide are effective anabolic therapies reducing vertebral and nonvertebral fractures.
• Common side effects include headache and nausea, with generally good tolerability.
• Prior antiresorptive exposure can reduce anabolic therapy benefits, but subsequent antiresorptive use consolidates gains.

Conclusions:

• Anabolic agents represent a critical therapeutic option for specific osteoporosis patient populations.
• Optimal sequencing involves considering prior antiresorptive use and planning post-anabolic antiresorptive therapy.
• Further research into anabolic agents like romosozumab may expand treatment options.